Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 30:7:119.
doi: 10.1186/1748-717X-7-119.

Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer

Xiao Ding  1 , Honghai Dai, Zhouguang Hui, Wei Ji, Jun Liang, Jima Lv, Zongmei Zhou, Weibo Yin, Jie He, Luhua Wang
Affiliations

Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer

Xiao Ding et al. Radiat Oncol. .

Abstract

Background: Brain metastases (BM) is one of the most common failures of locally advanced non-small cell lung cancer (LA-NSCLC) after combined-modality therapy. The outcome of trials on prophylactic cranial irradiation (PCI) has prompted us to identify the highest-risk subset most likely to benefit from PCI. Focusing on patients with completely resected pathological stage IIIA-N2 (pIIIA-N2) NSCLC, we aimed to assess risk factors of BM and to define the highest-risk subset.

Methods: Between 2003 and 2005, the records of 217 consecutive patients with pIIIA-N2 NSCLC in our institution were reviewed. The cumulative incidence of BM was estimated using the Kaplan-Meier method, and differences between the groups were analyzed using log-rank test. Multivariate Cox regression analysis was applied to assess risk factors of BM.

Results: Fifty-three (24.4 %) patients developed BM at some point during their clinical course. On multivariate analysis, non-squamous cell cancer (relative risk [RR]: 4.13, 95 % CI: 1.86-9.19; P = 0.001) and the ratio of metastatic to examined nodes or lymph node ratio (LNR) ≥ 30 % (RR: 3.33, 95 % CI: 1.79-6.18; P = 0.000) were found to be associated with an increased risk of BM. In patients with non-squamous cell cancer and LNR ≥ 30 %, the 5-year actuarial risk of BM was 57.3 %.

Conclusions: In NSCLC, patients with completely resected pIIIA-N2 non-squamous cell cancer and LNR ≥ 30 % are at the highest risk for BM, and are most likely to benefit from PCI. Further studies are warranted to investigate the effect of PCI on this subset of patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival for the 217 patients.
Figure 2
Figure 2
Disease-free survival (DFS) for the 217 patients.
Figure 3
Figure 3
Time to locoregional recurrence for the 217 patients.
Figure 4
Figure 4
Time to distant metastasis for the 217 patients.
Figure 5
Figure 5
The actuarial risk of developing brain metastases (BM) for the 217 patients.
Figure 6
Figure 6
Comparison of the actuarial risk of developing brain metastases (BM) between squamous cell cancer and non squamous cell cancer.
Figure 7
Figure 7
Comparison of the actuarial risk of developing brain metastases (BM) between lymph node ratio (LNR) ≥ 30 % and LNR < 30 %.
Figure 8
Figure 8
Comparison of the actuarial risk of developing brain metastases (BM) among patients with two, one, and none of the two risk factors, non-squamous cell cancer histology and lymph node ratio (LNR) ≥ 30 %.
See this image and copyright information in PMC

References

    1. Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94:2698–2705. doi: 10.1002/cncr.10541. - DOI - PubMed
    1. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, Ginsberg RJ. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995;109:120–129. doi: 10.1016/S0022-5223(95)70427-2. - DOI - PubMed
    1. Newman SJ, Hansen HH. Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer. 1974;33:492–496. doi: 10.1002/1097-0142(197402)33:2<492::AID-CNCR2820330225>3.0.CO;2-O. - DOI - PubMed
    1. Sorensen JB, Hansen H, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988;6:1474–1480. - PubMed
    1. Komaki R, Scott CB, Sause WT, Johnson DH, Taylor SG. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88–08/ECOG 4588. Int J Radiat Oncol Biol Phys. 1997;39:537–544. doi: 10.1016/S0360-3016(97)00365-9. - DOI - PubMed